Top

Published in:

01-01-2012 | Original Article

Fracture risk assessment without bone density measurement in routine clinical practice

Authors: W. D. Leslie, S. Morin, L. M. Lix, H. Johansson, A. Oden, E. McCloskey, J. A. Kanis, for the Manitoba Bone Density Program

Published in: Osteoporosis International | Issue 1/2012

Abstract

Summary

Fracture probability assessed without bone mineral density (BMD) could potentially be sufficient for clinical decision making in many individuals categorized as low or high fracture risk. For individuals falling in a moderate risk range, there is incremental value in using BMD in the probability calculation as this appropriately reclassifies risk in over one third of the individuals.

Introduction

A new fracture risk assessment tool from the World Health Organization (FRAX®) estimates 10-year major osteoporotic and hip fracture probabilities from multiple clinical risk factors with or without hip BMD. The objective of this study is to determine whether fracture probability derived without BMD can be used to identify individuals who would be designated for treatment.

Methods

A historical cohort of 36,730 women and 2,873 men aged 50 years and older drawn from the Manitoba Bone Density Program database, which contains clinical BMD results for the Province of Manitoba, Canada, was included in the study.

Results

When 10-year probability for major osteoporotic fracture estimated without knowledge of BMD was high (≥20%), the vast majority (92.8%) qualified for intervention under the National Osteoporosis Foundation (NOF) guidelines, whereas among those at low risk (<10%), the vast majority (80.5%) did not satisfy any NOF intervention criteria. The benefit of including BMD in the risk assessment was greatest among those initially at moderate risk (10–19%) when fracture probability was derived without BMD, but this represented only 29.4% of the cohort (9.3% of those aged <65 years and 48.7% of those ≥65 years).

Conclusions

Fracture probability derived without BMD is able to risk stratify women in terms of future fracture risk and could potentially be sufficient for clinical decision making in many of those designated at low or high fracture risk.

Available only for authorised users

NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef

Wiktorowicz ME, Goeree R, Papaioannou A et al (2001) Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 12:271–278PubMedCrossRef

Papaioannou A, Wiktorowicz ME, Adachi JD et al (2000) Mortality, independence in living and re-fracture, one year following hip fracture in Canadians. J Soc Obstet Gynaecol Can 22:591–597

Kanis JA, Oden A, Johnell O et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRef

Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581–589PubMedCrossRef

Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report, WHO Collaborating Centre for metabolic Bone Disease, University of Sheffield, UK. Available at http://www.shef.ac.uk/FRAX

Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCrossRef

Dawson-Hughes B (2008) A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463–2465PubMedCrossRef

Dawson-Hughes B, Tosteson AN, Melton LJ III et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449–458PubMedCrossRef

10.

Kanis JA, McCloskey EV, Johansson H et al (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRef

11.

Lippuner K, Johansson H, Kanis JA et al (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–389PubMedCrossRef

12.

Kanis JA, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef

13.

Fujiwara S, Kasagi F, Masunari N et al (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547–1553PubMedCrossRef

14.

Neuprez A, Johansson H, Kanis JA et al (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 64:612–619PubMed

15.

Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873PubMedCrossRef

16.

Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef

17.

Leslie WD, MacWilliam L, Lix L et al (2005) A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int 16:773–782PubMedCrossRef

18.

Leslie WD, Caetano PA, MacWilliam LR et al (2005) Construction and validation of a population-based bone densitometry database. J Clin Densitom 8:25–30PubMedCrossRef

19.

Kanis JA, McCloskey EV, Johansson H et al (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMedCrossRef

20.

Hansen KE, Binkley N, Christian R et al (2005) Interobserver reproducibility of criteria for vertebral body exclusion. J Bone Miner Res 20:501–508PubMedCrossRef

21.

Roos NP, Shapiro E (1999) Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care 37:JS10–JS14PubMedCrossRef

22.

Kozyrskyj AL, Mustard CA (1998) Validation of an electronic, population-based prescription database. Ann Pharmacother 32:1152–1157PubMedCrossRef

23.

Leslie WD, Tsang JF, Caetano PA et al (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92:77–81PubMedCrossRef

24.

Leslie WD, Lix LM, Johansson H et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358PubMedCrossRef

25.

Fraser LA, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRef

26.

Siminoski K, Leslie WD, Frame H et al (2005) Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 56:178–188PubMed

27.

Tosteson AN, Melton LJ III, Dawson-Hughes B et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCrossRef

28.

Tosteson AN, Burge RT, Marshall DA et al (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 14:605–615PubMed

29.

Satagopan JM, Ben-Porat L, Berwick M et al (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229–1235PubMedCrossRef

30.

Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr et al (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172PubMedCrossRef

31.

Janes H, Pepe MS, Gu W (2008) Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 149:751–760PubMed

32.

Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238PubMedCrossRef

33.

Curtis JR, Laster A, Becker DJ et al (2009) The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States. Osteoporos Int 20:1553–1561PubMedCrossRef

34.

Johansson H, Oden A, Johnell O et al (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913PubMedCrossRef

35.

Kanis JA, Johansson H, Oden A et al (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054PubMedCrossRef

36.

McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817PubMedCrossRef

37.

McCloskey EV, Lewiecki M, Kanis JA et al (2011) Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. Osteoporos Int 22(supplement 1):S103

38.

Kanis JA, Johansson H, Oden A et al (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735PubMedCrossRef

39.

Kanis JA, Johansson H, Oden A et al (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Osteoporos Int 22:2347–2355PubMedCrossRef

40.

Kanis JA, Johansson H, Oden A et al (2011) Erratum to: A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Osteoporos Int 22:2357–2358CrossRef

41.

Donaldson MG, Cawthon PM, Lui LY et al (2009) Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res 24:675–680PubMedCrossRef

42.

Donaldson MG, Cawthon PM, Lui LY et al (2010) Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 25:1506–1511PubMedCrossRef

43.

Berry SD, Kiel DP, Donaldson MG et al (2010) Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int 21:53–60PubMedCrossRef

44.

Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800PubMed

Title: Fracture risk assessment without bone density measurement in routine clinical practice
Authors: W. D. Leslie
S. Morin
L. M. Lix
H. Johansson
A. Oden
E. McCloskey
J. A. Kanis
for the Manitoba Bone Density Program
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 1/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1747-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fracture risk assessment without bone density measurement in routine clinical practice

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Pattern of use of DXA scans in men: a cross-sectional, population-based study

Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women

The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass—a randomized controlled 1-year trial

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists